Company Filing History:
Years Active: 2016
Title: Katrin Kaldma: Innovator in Immunological Adjuvants
Introduction
Katrin Kaldma is a prominent inventor based in Tartu, Estonia. She has made significant contributions to the field of immunology through her innovative research and development of novel adjuvants. Her work focuses on enhancing vaccine efficacy, which is crucial in the fight against various diseases.
Latest Patents
Kaldma holds a patent for an "Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant." This invention relates to an alphaviral replicase, particularly the Semliki Forest Virus replicase, or an expression vector encoding this replicase. The alphaviral replicase exhibits RNA-dependent RNA polymerase activity and is designed for use as an immune system modulating adjuvant. The invention aims to provide an efficient and easy-to-administer, species-independent adjuvant that offers advantages over current adjuvants used in conjunction with vaccines.
Career Highlights
Kaldma is associated with Fit Biotech Oy, a company dedicated to advancing biotechnological solutions. Her work at the company has been instrumental in developing innovative approaches to vaccine enhancement. With her expertise, she has contributed to the advancement of immunological research and the development of effective vaccines.
Collaborations
Kaldma collaborates with notable colleagues, including Kaja Kiiver and Rein Sikut. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of immunology.
Conclusion
Katrin Kaldma's contributions to immunological adjuvants highlight her role as a leading inventor in the field. Her innovative patent and collaborative efforts continue to pave the way for advancements in vaccine technology.